Survival and morbidity outcomes after pelvic exenteration for pelvic sarcoma: an institutional series.
margins of excision
morbidity
pelvic exenteration
sarcoma
survival
Journal
ANZ journal of surgery
ISSN: 1445-2197
Titre abrégé: ANZ J Surg
Pays: Australia
ID NLM: 101086634
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
31
07
2021
received:
17
05
2021
accepted:
17
09
2021
pubmed:
19
10
2021
medline:
12
5
2022
entrez:
18
10
2021
Statut:
ppublish
Résumé
To describe our institutional experience in the management of locally advanced primary, and recurrent pelvic sarcoma through pelvic exenteration (PE). Patients undergoing PE for locally advanced primary or recurrent pelvic sarcoma between 2003 and 2017 were identified from a prospectively maintained database at a single quaternary referral hospital in Sydney, Australia were eligible for review. The primary outcomes measured were surgical resection margin and survival. Secondary outcome measures included 30-day morbidity, in hospital length of stay (LOS) and return to theatre. There were 29 patients who underwent PE for pelvic sarcoma during the study period, with 55% (n = 16) having advanced primary tumours and 45% (n = 13) having recurrent disease. The R0 resection rate was 52% (n = 15); and five-year-survival of 38% (n = 11). The R0 resection was noted to be higher in patients having primary advanced tumours (56%) compared to those with recurrent disease (46%), however this failed to reach statistical significance in this cohort. There was no recorded 30-day mortality. Grade 3 or higher Clavien-Dindo complications were uncommon (14%), but more likely in patients undergoing surgery for recurrent disease (75%). In our cohort of patients with locally advanced and recurrent disease, more than 50% achieved an R0 resection. Recurrent disease makes R0 resection more difficult and can lead to higher morbidity, need for 30-day re-intervention and longer in hospital LOS. PE surgery remains the only curative option for locally advanced, and recurrent sarcoma in the pelvis, and can be performed with acceptable survival and morbidity outcomes.
Sections du résumé
BACKGROUND
To describe our institutional experience in the management of locally advanced primary, and recurrent pelvic sarcoma through pelvic exenteration (PE).
METHODS
Patients undergoing PE for locally advanced primary or recurrent pelvic sarcoma between 2003 and 2017 were identified from a prospectively maintained database at a single quaternary referral hospital in Sydney, Australia were eligible for review. The primary outcomes measured were surgical resection margin and survival. Secondary outcome measures included 30-day morbidity, in hospital length of stay (LOS) and return to theatre.
RESULTS
There were 29 patients who underwent PE for pelvic sarcoma during the study period, with 55% (n = 16) having advanced primary tumours and 45% (n = 13) having recurrent disease. The R0 resection rate was 52% (n = 15); and five-year-survival of 38% (n = 11). The R0 resection was noted to be higher in patients having primary advanced tumours (56%) compared to those with recurrent disease (46%), however this failed to reach statistical significance in this cohort. There was no recorded 30-day mortality. Grade 3 or higher Clavien-Dindo complications were uncommon (14%), but more likely in patients undergoing surgery for recurrent disease (75%).
CONCLUSION
In our cohort of patients with locally advanced and recurrent disease, more than 50% achieved an R0 resection. Recurrent disease makes R0 resection more difficult and can lead to higher morbidity, need for 30-day re-intervention and longer in hospital LOS. PE surgery remains the only curative option for locally advanced, and recurrent sarcoma in the pelvis, and can be performed with acceptable survival and morbidity outcomes.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1038-1043Informations de copyright
© 2021 Royal Australasian College of Surgeons.
Références
Keyzer-Dekker CMG, Houtkamp RG, Peterse JL, van Coevorden F. Adult pelvic sarcomas: a heterogenous collection of sarcomas? Sarcoma 2004; 8: 19-24.
Heslin MJ, Lewis JJ, Nadler E et al. Prognostic factors associated with long-term survival for retroperitoneal sarcoma: implications for management. J. Clin. Oncol. 1997; 15: 2832-9.
Bonvalot S, Rivoire M, Castaing M et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. J. Clin. Oncol. 2009; 27: 31-7.
Abdelfatah E, Guzzetta AA, Nagarajan N et al. Long-term outcomes in treatment of retroperitoneal sarcomas: a 15 year single-institution evaluation of prognostic features. J. Surg. Oncol. 2016; 114: 56-64.
Austin KS, Herd AJ, Solomon MJ, Ly K, Lee PJ. Outcomes of pelvic exenteration with en bloc partial or complete pubic bone excision for locally advanced primary or recurrent pelvic cancer. Dis. Colon Rectum 2016; 59: 831-5.
Brown KGM, Solomon MJ, Koh CE. Pelvic Exenteration surgery: the evolution of radical surgical techniques for advanced and recurrent pelvic malignancy. Dis. Colon Rectum 2017; 60: 745-54.
Austin K, Young JM, Solomon M. Quality of life of survivors after pelvic exenteration for rectal cancer. Dis. Colon Rectum 2010; 53: 1121-6.
Bacalbasa N, Balescu I. Pelvic exenteration-reconsidering the procedure. J. Med. Life 2015; 8: 146-9.
Shaik I, Aston W, Hellawell G et al. Extended lateral pelvic sidewall excision (ELSie): an approach to optimize complete resection rates in locally advanced or recurrent anorectal cancer involving the pelvic sidewall. Tech. Coloproctol. 2015; 19: 119-20.
Lau YC, Brown KG, Lee PJ. Pelvic exenteration for locally advanced and recurrent rectal cancer - how much more? J. Gastrointest. Oncol. 2019; 10: 1207-14.
Solomon MJ, Tan KK, Bromilow RG, Al-Mozany N, Lee PJ. Sacrectomy via the abdominal approach during pelvic exenteration. Dis. Colon Rectum 2014; 57: 272-7.
Brown KG, Solomon MJ, Latif ER et al. Urological complications after cystectomy as part of pelvic exenteration are higher than that after cystectomy for primary bladder malignancy. J. Surg. Oncol. 2017; 115: 307-11.
Austin KK, Solomon MJ. Pelvic exenteration with en bloc iliac vessel resection for lateral pelvic wall involvement. Dis. Colon Rectum 2009; 52: 1223-33.
Brown KG, Koh CE, Solomon MJ, Qasabian R, Robinson D, Dubenec S. Outcomes after en bloc iliac vessel excision and reconstruction during pelvic exenteration. Dis. Colon Rectum 2015; 58: 850-6.
Almond LM, Gronchi A, Strauss D, Jafri M, Ford D, Desai A. Neoadjuvant and adjuvant strategies in retroperitoneal sarcoma. Eur. J. Surg. Oncol. 2018; 44: 571-9.
Esnaola NF, Cantor SB, Johnson ML et al. Pain and quality of life after treatment in patients with locally recurrent rectal cancer. J. Clin. Oncol. 2016; 20: 4361-7.
Solomon MJ. Redefining the boundaries of advanced pelvic oncology surgery. Br. J. Surg. 2021; 108: 453-5.
PelvExCollaborative. Pelvic exenteration for advanced nonrectal pelvic malignancy. Ann. Surg. 2019; 270: 899-905.
Ferenschild FT, Vermaas M, Verhoef C et al. Total pelvic exenteration for primary and recurrent malignancies. World J. Surg. 2009; 33: 1502-8.
Lopez MJ, Standiford SB, Skibba JL. Total pelvic exenteration: a 50-year experience at the Ellis Fischel Cancer Center. Arch. Surg. 1994; 129: 390-6.
Houvenaeghel G, Moutardier V, Karsenty G et al. Major complications of urinary diversion after pelvic exenteration for gynecologic malignancies: a 23-year mono-institutional experience in 124 patients. Gynecol. Oncol. 2004; 92: 680-3.
Bonvalot S, Gronchi A, Le Pechoux C et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020; 21: 1366-77.
Le Pechoux C, Musat E, Baey C et al. Should adjuvant radiotherapy be administered in addition to front-line aggressive surgery (FAS) in patients with primary retroperitoneal sarcoma? Ann. Oncol. 2013; 24: 832-7.
Haas RL, Baldini EH, Chung PW, van Coevorden F, DeLaney TF. Radiation therapy in retroperitoneal sarcoma management. J. Surg. Oncol. 2018; 117: 93-8.
Woll PJ, Reichardt P, Le Cesne A et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012; 13: 1045-54.
PelvEx Collaborative. Changing outcomes following pelvic exenteration for locally advanced and recurrent rectal cancer. BJS Open. 2019; 3: 516-20.
Swallow CJ, Strauss DC, Bonvalot S et al. Management of primary retroperitoneal sarcoma (RPS) in the adult: an updated consensus approach from the Transatlantic Australasian RPS Working Group. Ann. Surg. Onc. [Online ahead of print] 2021. https://doi.org/10.1245/s10434-021-09654-z.